Drawing for RIBOZYME PHARMACEUTICALS INCORPORATED

USPTO serial 74500487

RIBOZYME PHARMACEUTICALS INCORPORATED

Reviewed by CopyMark Law Group

Reg. 2104350Status 710
Filing date
Status date
Registration date
Oct 7, 1997
Examiner
SUSSMAN, RONALD
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with RIBOZYME PHARMACEUTICALS INCORPORATED?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David A. Randall

JAMES M MCCARTHY MCDONNELL BOEHNEN HULBERT & BERGHOFFSTE 3200300 S WACKER DRCHICAGO, IL 60606

Goods and services

ClassDescriptionStatusFirst use
005medicinal drug and biological preparations and products for the treatment of human diseases involving abnormal protein synthesisSECTION 8 - CANCELLEDMar 25, 1994

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 10, 2004C8..CANCELLED SEC. 8 (6-YR)—
Oct 25, 2002TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 7, 1997R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Aug 18, 1997CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER—
Aug 18, 1997IUAAUSE AMENDMENT ACCEPTED—
May 21, 1997AUPCAMENDMENT TO USE PROCESSING COMPLETE—
May 1, 1997IUAFUSE AMENDMENT FILED—
Jan 23, 1997CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 25, 1996DOCKASSIGNED TO EXAMINER—
Mar 11, 1996CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 11, 1996DOCKASSIGNED TO EXAMINER—
Nov 20, 1995CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 18, 1995CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 14, 1995CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 14, 1994CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

Frequently asked questions

Related guidance